Improvement of accessory symptoms of hypertension by TSUMURA Orengedokuto Extract, a four herbal drugs containing Kampo-Medicine Granules for ethical use: A double-blind, placebo-controlled study

被引：24

作者：

Arakawa, K

Saruta, T

Abe, K

Iimura, O

Ishii, M

Ogihara, T

Hiwada, K

Fukiyama, K

Fujishima, M

Mizuno, Y

Kikuchi, T

Takaori, S

机构：

[1] Fukuoka Univ, Sch Med, Dept Internal Med 2, Fukuoka 81401, Japan

[2] Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan

[3] Tohoku Univ, Sch Med, Dept Internal Med 2, Sendai, Miyagi 980, Japan

[4] Sapporo Med Univ, Sch Med, Dept Internal Med 2, Sapporo, Hokkaido, Japan

[5] Yokohama City Univ, Sch Med, Dept Internal Med 2, Yokohama, Kanagawa 232, Japan

[6] Osaka Univ, Dept Geriatr Med, Fac Med, Suita, Osaka, Japan

[7] Ehime Univ, Sch Med, Dept Internal Med 2, Matsuyama, Ehime, Japan

[8] Univ Ryukyus, Fac Med, Dept Internal Med 3, Okinawa, Japan

[9] Kyushu Univ, Fac Med, Dept Internal Med 2, Fukuoka 812, Japan

[10] Fujita Hlth Univ, Sch Med, Dept Internal Med, Nagoya, Aichi, Japan

[11] Sakakibara Heart Inst, Tokyo, Japan

[12] Shimane Med Univ, Izumo, Shimane 693, Japan

来源：

PHYTOMEDICINE | 2006年 / 13卷 / 1-2期

关键词：

Orengedokuto; Kampo medicine (Japanese herbal medicine); double-blind; placebo-controlled study; accessory symptoms of hypertension;

D O I：

10.1016/j.phymed.2004.02.012

中图分类号：

Q94 [植物学];

学科分类号：

071001 [植物学];

摘要：

A double-blind, placebo-controlled study was conducted to evaluate the efficacy, safety, and utility of TSUMURA Orengedokuto Extract Granules for Ethical Use (TJ-15) as a treatment for the accessory symptoms of hypertension. Two capsules of the study drug were administered orally 3 times daily (i.e., before meals) for 8 weeks. Among 265 patients enrolled in the study, 134 were assigned to the TJ-15 group and 131 were assigned to the placebo group, of whom 204 patients (103 in the TJ-15 group and 101 in the placebo group) were included in the efficacy and utility analyze and 251 patients (128 in the TJ-15 group and 123 in the placebo group) were included in the safety analysis.

引用

页码：1 / 10

页数：10

共 8 条

[1]

ARAKAWA K, 1987, J MED PHARM SOC WAKA, V4, P35

[2]

DIFFERENCES IN THE SUBJECTIVE WELL-BEING AND SYMPTOMS OF NORMOTENSIVES, BORDERLINE HYPERTENSIVES AND HYPERTENSIVES [J].

DIMENAS, ES ;

WIKLUND, IK ;

DAHLOF, CG ;

LINDVALL, KG ;

OLOFSSON, BK ;

DEFAIRE, UH .

JOURNAL OF HYPERTENSION, 1989, 7 (11) :885-890

[3]

*GUID SUBC JAP SOC, 2000, GUID MAN HYP

[4]

HAYASHI T, 1991, J KANSAI MED U, V43, P421

[5]

Ito E, 1991, GERIATR MED, V29, P303

[6]

NAGASAWA H, 1994, DEMENTIA, V8, P303

[7]

OTSUKA K, 1986, STANDARD PRACTICE KA

[8]

Wakita H., 2002, Journal of Traditional Medicines, V19, P230

← 1 →